Lower Inspiratory Oxygen Fraction for Preoxygenation

February 24, 2019 updated by: E-DA Hospital

Effects of Preoxygenation With Lower Inspiratory Oxygen Fraction During Induction of Anesthesia

During the induction period of general anesthesia, surgical patients are inevitably experienced a short period of apnea for endotracheal intubation or other airway manipulation. In order to minimize the risks of hypoxemia during the establishment of artificial airway, pure oxygen (FiO2=100%) is commonly applied to the patients throughout the preoxygenation and induction period. However, high concentration of oxygen therapy has been shown to result in hyperoxemia and substantial oxygen exposure during perioperative period or critical care. There is currently no clinical evidence indicating that preoxygenation with a lower oxygen partial pressure (such as FiO2=60%) during the induction of anesthesia increases the incidence of hypoxemia or other complications. The findings of this proposed clinical study may provide fundamental evidence for the use of different oxygen concentrations in clinical anesthesia during the induction period, and determine the effects of inspired oxygen concentrations on the general postoperative outcomes during general anesthesia.

Study Overview

Detailed Description

The administration of 100% oxygen for 3-5 minutes may replace the nitrogen content in the lung cavity (de-nitrogenation) with higher alveolar concentrations of oxygen (greater then 95%). Elevation of oxygen reserve in the lung and oxygen partial pressure in the blood circulation may thus delay the development of hypoxemia (oxygen desaturation; defined as the tissue oxygen saturation below 90%) up to 10 minutes after apnea.

On the other hand, there is currently no clinical evidence indicating that preoxygenation with lower oxygen partial pressures (i.e. FiO2= 50-60%) during the induction of anesthesia increases the incidence of hypoxemia or other complications. Most recently, two elegant large-scale clinical trials reported that the supplement of oxygen to patients with acute myocardial infarction or acute ischemic stroke did not provide any clinically beneficial effects in the prognosis of diseases. The results of these two important trials did not support the routine supplement of oxygen in these acute diseases. In addition, high concentrations of oxygen therapy are potentially deleterious, as oxygen toxicity may result in direct tracheobronchial and alveolar damage, absorption atelectasis (lung tissue collapse) and central nervous system toxicity. In cellular levels, hyperoxia increases the production of reactive oxygen species, such as the superoxide anion, the hydroxyl radical, and hydrogen peroxide, which in turn may cause cellular apoptosis and inflammatory response. Therefore, oxygen therapy in clinical settings has been recognized as a two-edged sword and excessive oxygen supplement should be guided closely for its potential toxicity.

Currently, there is no clinical evidence that supports the routine administration of 100% oxygen prior to intubation is essential or beneficial. In the contrary, it also remains undetermined if lower fractions of inspiratory oxygen during the induction period of anesthesia may attenuate lung injury or other cellular damage derived from the oxygen toxicity. Therefore, the findings of this proposed clinical study may provide fundamental evidence for the use of different oxygen concentrations in clinical anesthesia during the induction period, and determine the effects of inspiratory oxygen concentrations on the general postoperative outcomes after general anesthesia.

This is a randomized, open-label, observer-blind and non-inferiority clinical trial.

The research model of study is two-group parallel interventional study. The control group is preoxygenation with 100% oxygen during the induction phase of anesthesia; the experimental group is preoxygenation with 60% oxygen during the induction phase of anesthesia. The anesthetists in-charge are not blinded to the concentrations of oxygen use during induction of anesthesia, but the persons who collected study data will be unaware of the treatment. Block randomization will be generated using a generator software and the assignment of treatment will be sealed in the envelops.

This study anticipates in enrolling 1500 participants.

Study Type

Interventional

Enrollment (Actual)

304

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Kaohsiung
      • Yanchao, Kaohsiung, Taiwan, 824
        • E-DA Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 63 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. A patient who is scheduled for an elective surgery and required for general anesthesia with endotracheal intubation.
  2. Age of the patient is between 20 and 65 years old.
  3. Patient's American Society of Anesthesiologists (ASA) Physical Status is I- III.

Exclusion Criteria:

Patients who:

  1. Have difficult airway for ventilation or intubation.
  2. Have severe lung disease (including any acute respiratory infection).
  3. Had past history of coronary artery disease or myocardial infarction.
  4. Have severe heart failure (NYHA Fc ≥III).
  5. Have liver cirrhosis (Child-Pugh's score ≥B).
  6. Have acute or chronic kidney disease (Creatinine ≥2 mg/dl).
  7. Have severe anemia (hemoglobin ≤8 mg /dl).
  8. Have a body mass index (BMI) ≥35.
  9. Are currently pregnant.
  10. Have inadequate fasting time, intestinal obstruction or severe gastroesophageal reflux.
  11. Scheduled for an emergency surgery, cardiac surgery, craniotomy, or pulmonary surgery.
  12. Have mental incapacitant, confusion, dementia, mental retardation, or are unable to complete the consent independently.
  13. Refuse to participate in this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Pure oxygen group
The patients receive 100% oxygen therapy during the induction phase of induction
pre-oxygenation with 100% oxygen during induction of anesthesia
Experimental: Lower oxygen group
The patients received 60% oxygen therapy during the induction phase of induction
Pre-oxygenation with 60% oxygen during induction of anesthesia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of hypoxemia
Time Frame: Within 30 minutes after induction of anesthesia
The definition of hypoxemia is the measurement of peripheral oxygen saturation (sPO2) lower than < 92%. Induction phase of anesthesia is defined as the time frame from preoxygenation before intravenous administration of anesthetics to successful establishment of an endotracheal tube.
Within 30 minutes after induction of anesthesia

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Development of acute respiratory distress syndrome (ARDS)
Time Frame: Within 7 days after surgery
ARDS is defined as any calculated PaO2/FiO2 less than 300mmHg with radiographic evidence of bilateral lung infiltration in the absence of left heart failure
Within 7 days after surgery
Development of atelectasis
Time Frame: Within 7 days after surgery
Atelectasis is defined as partial or complete collapse of lung lobe(s) on chest radiography
Within 7 days after surgery
Development of pneumonia
Time Frame: Within 7 days after surgery
Pneumonia is defined as acute infection of lung parenchyma
Within 7 days after surgery
Development of surgical site infection (SSI)
Time Frame: Within 7 days after surgery
SSI is defined as infection arising from surgical incision
Within 7 days after surgery
Development of severe postoperative pain
Time Frame: Within 7 days after surgery
Severe postoperative pain is defined as visual analogue scale (VAS) >4 despite of administration of analgesics. VAS is defined as a straight line with the endpoints representing the extreme limits of pain; "no pain at all= 0" and "pain as bad as it could be= 10"
Within 7 days after surgery
Length of hospital stay (LOS)
Time Frame: Within 7 days after surgery
LOS is defined as day(s) of hospitalization after surgery
Within 7 days after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Chen-Fuh Lam, MD, PhD, E-DA Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2018

Primary Completion (Actual)

January 31, 2019

Study Completion (Actual)

January 31, 2019

Study Registration Dates

First Submitted

September 2, 2018

First Submitted That Met QC Criteria

September 10, 2018

First Posted (Actual)

September 11, 2018

Study Record Updates

Last Update Posted (Actual)

February 27, 2019

Last Update Submitted That Met QC Criteria

February 24, 2019

Last Verified

September 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Oxygen Deficiency

Clinical Trials on Pure oxygen group

3
Subscribe